Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Jaguar Health (JAGX) EPS (Weighted Average and Diluted) (2016 - 2025)

Jaguar Health (JAGX) has disclosed EPS (Weighted Average and Diluted) for 9 consecutive years, with $4.17 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 497.14% to $4.17 in Q3 2025 year-over-year; TTM through Sep 2025 was -$2.58, a 99.9% increase, with the full-year FY2024 number at -$130.69, up 95.12% from a year prior.
  • EPS (Weighted Average and Diluted) was $4.17 for Q3 2025 at Jaguar Health, up from -$10.08 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $20.03 in Q4 2024 to a low of -$2611.9 in Q4 2023.
  • A 5-year average of -$154.54 and a median of -$8.83 in 2022 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 9800.95% in 2021, then soared 497.14% in 2025.
  • Jaguar Health's EPS (Weighted Average and Diluted) stood at -$87.35 in 2021, then soared by 59.14% to -$35.69 in 2022, then tumbled by 7218.38% to -$2611.9 in 2023, then soared by 100.77% to $20.03 in 2024, then crashed by 79.18% to $4.17 in 2025.
  • Per Business Quant, the three most recent readings for JAGX's EPS (Weighted Average and Diluted) are $4.17 (Q3 2025), -$10.08 (Q2 2025), and -$16.7 (Q1 2025).